Therapeutic Target-Humanized Mice
Cre/Dre-Driver Mice
Immunodeficient NMG Mice
F0 homozygous mice gene knockout Crispr/Cas projects immediate phenotype analysis research efficiency cost optimization.
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Antibody-Drug Conjugates ADC Development Preclinical Models Targeted Cancer Therapies GenoBioTX ADC Webinar Biopharma Research Oncology Biochemistry Cancer Treatment Preclinical Evaluation Monoclonal Antibodies Small Molecule Drugs
Join us for a webinar on June 26th, 2024, exploring the development and preclinical evaluation of Antibody-Drug Conjugates (ADCs). Learn from Dr. Hua Wei, VP of the Industrial Clients Department at GenoBioTX, about ADC components, mechanisms, historical evolution, and future directions.
Bone metastasis cancer model Pain-related behavior assessment Cancer-induced bone pain Bone cancer pain models Mouse bone metastasis model Animal models in cancer research Cancer research services Bone metastasis in mice Pain management in cancer
We are excited to announce that GenoBioTX has launched a new service featuring mouse bone metastasis cancer models and pain-related behavior assessment, designed to support cancer research and pain management effectively.
Discover cutting-edge strategies and applications of genetically modified mice in biomedical research at our webinar on May 23rd, 2024. Register now for insights from industry expert Dongxiao Feng
bronchioalveolar stem cells lung repair lung regeneration
Published on today's Nature Genetics, Prof. Bin Zhou's research group from Shanghai Institute of Biochemistry and Cell Biology revealed the bona fide role of bronchioalveolar stem cells (BASC) during lung repair and regeneration.
Shanghai Model Organisms
After the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.
On March 22, Dr. Ruilin Sun, the deputy general manager of SMOC, gave a seminar on how to generate, breed and use genetically modified mouse models for biomedical research, at Wenzhou Medical University.
CRISPR-Cas9 technology Broad Institute genetically modified mouse
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Please fill in the order form and we will contact you within 2 working days.
